From the Weekly free Bull Newsletter which also includes IHL and...

From the Weekly free Bull Newsletter which also includes IHL and KZA in the article:

Argenica Therapeutics listed on the ASX in June of 2021 to bring to market a “neuroprotective” treatment developed at the University of Western Australia by Professors Bruno Meloni and Neville Knuckey. The drug — ARG-007 – can provide protection to the brain following stroke disorders and other acute injuries to the central nervous system. The drug is designed to stop further brain tissue death following strokes and related injuries, with initial treatments provided by first responders.

Following the December of 2021 announcement that Argenica had received a “notice of allowance” by the United States Patent and Trademark Office with the expectation that this preliminary patent approval would become formal within months, the company released a series of announcements regarding progress of pre-clinical studies needed prior to the commencement of a formal Phase I clinical trial.

Two early progress announcements were followed by the release of a “peer-reviewed “ scientific paper authored by one of the developers of ARG-007. Then came two more announcements with details of successful animal studies necessary for a final ethics submissions before approval.

On 4 May Argenica announced that all the safety preclinical pharmacology studies required for a Phase I trial ethics submission had been completed.

However, investors were disappointed to learn an additional step was needed prior to the completion of the ethics submission. Argenica management expects the step to be completed soon with the expectation that the Phase I trial could begin in the current Quarter. The stock price took a dip, but began recovering within two days, perhaps in anticipation of the next announcement.